SecurityWFC.PRY / Wells Fargo & Company
CEO & PresidentSLOAN TIMOTHY J
IndustryNational Commercial Banks
Institutional Owners0
Common Shares Outstanding4,816,137,157 shares (as of 2018-06-30)
Related 33738MAB7 / 1st Un Natl Bk Charlotte Mtnbe Fr 6.5% 12/01/2028
33738MAA9 / 1st Un Natl Bk Charlotte Mtnbe Put 6.18% 02/22/2036
33738MAG6 / 1st Un Natl Bk Charlotte Mtnbe Put 6.919% 12/15/2036
33738KAA3 / 1st Un Natl Bk Jacksonvi Mtnbe Fr 6.18% 02/15/2036
337358BD6 / First Union Corp 6.55% Sub Debs 10/15/35
337358BA2 / First Union Corp 7.5% Sub Debs 4/15/35
66938FJU9 / Norwest Corp Medterm Notes Bk En Fr 6.75% 12/15/27
669380AW7 / Norwest Corp Sub Debentures 6.65% 10/15/23
8447HEAA4 / Southtrust Bk Atlanta Sub Mtn Put 7.74% 05/15/2025
8447HBAC6 / Southtrust Bk Birmgham Sub Mtn Fr 6.565% 12/15/27
8447HBAE2 / Southtrust Bk Birmgham Sub Mtn Put 6.125% 01/09/2028
8447HBAA0 / Southtrust Bk Birmgham Sub Mtn Put 7.69% 05/15/2025
844730AG6 / Southtrust Corp Subordinated Notes 5.8% 06/15/14
92976GAE1 / Wachovia Bk Natl Assn Mtn Sub Call 5.6% 03/15/16
92976GAB7 / Wachovia Bk Natl Assn Mtn Sub Fr 4.8% 11/01/2014
92976GAD3 / Wachovia Bk Natl Assn Mtn Sub Fr 4.875% 02/01/2015
92976GAA9 / Wachovia Bk Natl Assn Mtn Sub Fr 5% 08/15/2015
92976GAG6 / Wachovia Bk Natl Assn Mtn Sub Fr 5.85% 02/01/2037
92976GAH4 / Wachovia Bk Natl Assn Mtn Sub Fr 6% 11/15/2017
92976GAJ0 / Wachovia Bk Natl Assn Mtn Sub Fr 6.6% 01/15/2038
92978AAA0 / Wachovia Capital Trust Iii 5.80
929903AE2 / Wachovia Corp 4.875% Subordinated Notes 02/15/14
929903AJ1 / Wachovia Corp 5.250% Subordinated Notes 08/01/14
929903AM4 / Wachovia Corp 5.5% Notes 8/1/2035
92976WBJ4 / Wachovia Corp. 5.5% Senior Notes 5/1/13
929903CH3 / Wachovia Corp 5.625% Notes 10/15/2016
929903DT6 / Wachovia Corp 5.75% Notes 6/15/17
92976WBH8 / Wachovia Corp 5.75% Senior Notes 2/1/18
92976WBA3 / Wachovia Corp 5.7% Notes 8/1/2013
929771AE3 / Wachovia Corp 6.605% Notes 10/1/2025
949746NX5 / Wells Fargo 5.625% Senior Notes 12/11/17
94980VAA6 / Wells Fargo Bank Na 4.75% 02/09/15
94978SAA7 / Wells Fargo Cap X Cap Sec 5.95% 12/01/86
WFC / Wells Fargo & Co.
WFCNP / Wells Fargo & Co.
94974BFA3 / Wells Fargo & Co. 1.25% 02/13/15
94974BFG0 / Wells Fargo & Co. 1.50% 01/16/18
94974BFE5 / Wells Fargo & Co. 1.50% 07/01/15
94974BFD7 / Wells Fargo & Co. 2.10% 05/08/17
94974BFJ4 / Wells Fargo & Co. 3.45% 02/13/23
94974BFC9 / Wells Fargo Co 3.50% Senior Notes 03/08/22
949746FS5 / Wells Fargo & Co 4.625% Subordinated Notes 4/15/14
949746FJ5 / Wells Fargo & Co 4.950% Subordinated Notes 10/16/13
949746CR0 / Wells Fargo & Co 5.000% Subordinated Notes 11/15/14
WFC.PRO / Wells Fargo & Co., 5.125% Dep Shares Non-Cumul Perp Preferred Stock Series O
949746JE2 / Wells Fargo & Co. 5.125% Notes 9/15/16
WFC.PRN / Wells Fargo & Co., 5.20% Dep Shares Non-cumul Perp Cl A Preferred Stock Series N
WFC.PRP / Wells Fargo & Co., 5.25% Dep Shares Non-Cumul Perp Preferred Stock Series P
949746JM4 / Wells Fargo & Co. 5.375% Notes 2/7/35
WFC.PRX / Wells Fargo & Co., 5.50% Dep Shares Non-Cumul Class A Preferred Stock Series X
WFC.PRW / Wells Fargo & Co., 5.70% Dep Shares Non-Cumul Class A Preferred Stock Series W
WFC.PRQ / Wells Fargo & Co., 5.85% Dep Shares Fixed/Float Non-Cumul Perp Pfd Stock Ser Q
WFC.PRT / Wells Fargo & Co., 6.00% Dep Shares Non-Cumul Class A Preferred Stock Series T
WFC.PRV / Wells Fargo & Co., 6.00% Dep Shares Non-Cumul Class A Preferred Stock Series V
WFC.PRR / Wells Fargo & Co., 6.625% Dep Shares Fixed/Float Non-Cumul Perp Pfd Stock Ser R
WFC.PRL / Wells Fargo & Co., 7.50% Non-Cumul Perp Conv Cl A Preferred Stock, Series L
WFC.PRJ / Wells Fargo & Co., 8.00% Dep Shares Non-cumul Perp Cl A Preferred Stock Series J
94974BFN5 / Wells Fargo & Co. Bond
94986RPJ4 / Wells Fargo & Co. Bond
94986RTK7 / Wells Fargo & Co. Bond
94974BEZ9 / Wells Fargo & Company 2.625% 12/15/16
94974BEU0 / Wells Fargo & Company 3.625% Senior Notes 04/15/15
94974BEV8 / Wells Fargo & Company 4.60% Notes 04/01/21
WFC.PRJCL / Wells Fargo & Company Depositary Shares (Each representing a 1/40th interest in a share of 8.00% Non
94974BET3 / Wells Fargo Co Mtn Be Senior Notes 3.75% 10/01/14
94986RFK2 / Wells Fargo & Co. SE
WFC.WS / Wells Fargo & Co. (Warrant)

Institutional Stock Ownership and Shareholders

Wells Fargo & Company (NYSE:WFC.PRY) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
Wells Fargo & Company (NYSE:WFC.PRY) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

4h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

Related News Stories

What Does A 'Frozen' Wells Fargo Look Like?

1h seekingalpha
To suggest that shares of San Francisco-based Wells Fargo (WFC) have lagged in the past few years could very well be an understatement. Consider that since July of 2015 shares of JPMorgan (JPM) and Bank of America (BAC) have increased by 70% and 72% respectively. Meanwhile, shares of Wells Fargo have actually declined slightly. (4-0)

Regional Banks Stocks Are Sliding Despite A Pending Rate Hike By The FOMC

4h seekingalpha
BB&T Corp, M&T Bank and PNC Financial peaked in late-February, mid-March and are now under “death cross” formations. (6-0)

Top Research Reports for Johnson & Johnson, Visa & Verizon

4h zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Visa (V) and Verizon (VZ). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. (35-0)

IHS Markit Ltd. (INFO) CEO Lance Uggla on Q3 2018 Results - Earnings Call Transcript

5h seekingalpha
IHS Markit Ltd. (NASDAQ:INFO) Q3 2018 Results Earnings Conference Call September 25, 2018 8:00 AM ET (4-0)

East Asia ETF Breakdown: Hong Kong, Malaysia, And South Korea

6h seekingalpha
The purpose of this article is to initiate a comparative analysis on exchange-traded funds within the Emerging Market segment. Countries in discussion are Hong Kong, Malaysia, and South Korea. The Malaysia and Hong Kong ETFs are cost efficient options compared to the South Korea one. At the same time, exposure to the financial sector is less in the South Korea ETF relative to both the Malaysia and Hong Kong ETFs. (41-0)

Nightstar Therapeutics: Sell-Off Is A Great Entry Point For Long-Term Investors

6h seekingalpha
At this weekend's EURETINA 2018, Nightstar Therapeutics presented promising data for its XIRIUS trial for the treatment of X-linked Retinitis Pigmentosa (XLRP). (7-0)

Wall St flat as losses in Facebook, chip stocks offset bank, energy gains

7h theedgemarkets
BENGALURU (Sept 25): US stocks were little changed on Tuesday, as higher oil prices lifted energy stocks and banks rose in anticipation of an interest rate hike, but losses in Facebook and chipmakers weighed on the market. (4-0)

Wall St flat as losses in Facebook, chip stocks offset bank, energy gains

7h malaymail
NEW YORK, Sept 25 — US stocks were little changed today, as higher oil prices lifted energy stocks and banks rose in anticipation of an interest rate hike, but losses in Facebook and chipmakers weighed on the market. (4-0)

US STOCKS-Wall St flat as losses in Facebook, chip stocks offset bank, energy gains

7h reuters
(Reuters) - U.S. stocks were little changed on Tuesday, as higher oil prices lifted energy stocks and banks rose in anticipation of an interest rate hike, but losses in Facebook and chipmakers weighed on the market. (4-0)

JPMorgan to Expand in Philadelphia, Open 50 Retail Branches

8h zacks
JPMorgan (JPM - Free Report) recently announced that seeks to expand in Philadelphia and the Delaware Valley. This is part of its plan to expand into 15-20 new markets. The bank will be opening 50 retail branches and hire around 300 new employees in the region by the end of 2023. Further, JPMorgan will invest $3 billion toward mortgage and small business lending in the area and $5 million to help revitalize Philadelphia's Kensington Avenue neighborhood over the next five years. (5-0)